No Data
Rendu Biotech (688193.SH) has obtained the medical instruments registration certificate for related products.
Rendu Biotechnology (688193.SH) announced that the company recently received the "Medical..." issued by the National Medical Products Administration.
Rendu Biotech: 2024 Annual Results Report
2024 Annual Results Report
2024 Annual Results Forecast
Rendu Bio (688193.SH): It is expected to have a net loss of 6.7 million to 10 million yuan in 2024.
Gelonghui, January 17: RenDu Biology (688193.SH) announced that 1. According to preliminary calculations by the finance department, the company expects to achieve a net income attributable to the parent company's owners of -6.7 million yuan to -10 million yuan in 2024, which represents a decrease of 14.96 million yuan to 18.26 million yuan compared to the same period last year (statutory disclosure data), a year-on-year decrease of 181% to 221%. 2. It is expected that the net income attributable to the parent company's owners, excluding non-recurring gains and losses, will be -18.05 million yuan to -21.35 million yuan in 2024, which is compared to the same period last year (statutory disclosure data).
Shanghai Rendu Biotechnology's (SHSE:688193) Solid Earnings May Rest On Weak Foundations
Shanghai Rendu Biotechnology Co., Ltd.'s (SHSE:688193) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
